Zynex (ZYXI) Interest Expense : $-1.5 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Zynex Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zynex's interest expense for the three months ended in Mar. 2024 was $ -0.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zynex's Operating Income for the three months ended in Mar. 2024 was $ 0.5 Mil. Zynex's Interest Expense for the three months ended in Mar. 2024 was $ -0.5 Mil. Zynex's Interest Coverage for the quarter that ended in Mar. 2024 was 1.03. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zynex Interest Expense Historical Data

The historical data trend for Zynex's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Interest Expense Chart

Zynex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.01

-0.02

-0.10

-0.44

-1.09

Zynex Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.08	-0.32	-0.33	-0.37	-0.51

Zynex Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.5 Mil.

Zynex (NAS:ZYXI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zynex's Interest Expense for the three months ended in Mar. 2024 was $-0.5 Mil. Its Operating Income for the three months ended in Mar. 2024 was $0.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $71.4 Mil.

Zynex's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	0.525	/	-0.512
	=	1.03

The higher the ratio, the stronger the company's financial strength is.

Zynex (ZYXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9555 Maroon Circle, Englewood, CO, USA, 80112

Website

https://www.zynex.com

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.

Executives

Daniel J Moorhead	officer: Chief Financial Officer	9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok	officer: See Remarks	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard	director, 10 percent owner, officer: President, CEO and Chairman	10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery	officer: See Remarks	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow	director	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress	director	3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc	10 percent owner	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea	officer: Chief Operating Officer	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112